Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambroxol hydrochloride + glucose injection is a mucolytic and expectorant formulation developed by Hebei Aier Haitai Technology. The active ingredient, ambroxol hydrochloride, is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It works by increasing the production of pulmonary surfactant, stimulating ciliary activity, and reducing mucus viscosity, thereby facilitating expectoration and easing cough. The glucose component serves as an isotonic vehicle for intravenous administration. This formulation is approved in China for indications including acute and chronic bronchitis, bronchial asthma, and the prevention of postoperative pulmonary complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol hydrochloride + glucose injection.